Race Against Time: The Challenge of Sepsis

Race Against Time: The Challenge of Sepsis Sepsis is life-threatening, costly and challenging to diagnose and treat. Learn from a panel of experts how laboratories and clinicians can work together to fight this deadly condition. See details AACC Scientific Session Sepsis affects approximately 30 million people worldwide every year and results in $24 billion in healthcare costs in the U.S. alone.1,2 Early detection and diagnosis are key to stopping its progression and require the collaboration of both clinicians and clinical laboratories. Attend A Race Against Time: The Challenge of Sepsis for Clinicians and Laboratorians, at the 71st AACC Annual Scientific Meeting in Anaheim to hear from a panel of experts as they discuss the latest insights into diagnosis and treatment of this deadly condition. Explore topics including: The healthcare burden of sepsis The clinical guidelines used in establishing a sepsis protocol The roles of various stakeholders in the diagnosis and management of sepsis Sepsis and antibiotic stewardship Space is limited. Reserve your seat now b: Beckman Coulter at AACC While youbre at AACC, donbt forget to visit Beckman Coulter at booth 3201. Check out cutting-edge advancements in clinical chemistry, hematology, clinical information management tools and more. Preview the innovations to be showcased at AACC b: 1Sepsis Alliance. bFact Sheet. 2018.b Sepsis.org. Accessed 6 Mar. 2019. 2Torio C, Moore B. bNational Inpatient Hospital Costs: The Most Expensive Conditions by Payer.b www.hcup-us.ahrq.gov/reports/ statbriefs/sb204-Most- Expensive-Hospital-Conditions. pdf, May 2016. Accessed 15 Jan. 2018. EM-212022-External-1-0 Follow us: Beckman Coulter, Inc., 25‌0 S. Kraemer B‌lvd., P.‌O. B‌ox 80‌00, Bre‌a, C‌A 92821, U‌SA B) 2019 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.